Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have led to hospitalisations and even deaths.

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan Skrmetti.

A unique business structure gives LifeMD access to the growing GLP-1 marketplace that can help boost the heavily shorted stock price. Read an analysis of LFMD here.

Overpaying for GLP-1 medications is extremely common, with a new data analysis of 102,166 drugs showing that 92% of those prescriptions could have been filled at a lower price. The DoseSpot analysis ...

MindRank has shared the skinny on its oral GLP-1 receptor agonist, publishing data from a Chinese phase 2b obesity trial that suggests efficacy is in the same ballpark as Eli Lilly’s orforglipron.

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with fat.

Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find out why NVO stock is a buy.

GLP-1 drugs such as Wegovy and Zepbound are growing increasingly prominent. But some food ingredients can also cause the body to release the GLP-1 hormone, helping consumers feel full. Ingredients ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who take the same medications. One possible reason for the weight loss ...